Abstract
Background Many countries have attempted to mitigate and control COVID-19 through the implementation of non-pharmaceutical interventions, particularly with the aim of reducing population movement and contact. However, it remains unclear how the different control strategies impacted the local phylodynamics of the causative SARS-CoV-2 virus.
Aim To assess the duration of chains of virus transmission within individual countries and the extent to which countries export viruses to their geographic neighbours.
Methods To address core questions in genomic epidemiology and public health we analysed complete SARS-CoV-2 genomes to infer the relative frequencies of virus importation and exportation, as well as virus transmission dynamics, within countries of northern Europe. To this end, we examined virus evolution and phylodynamics in Denmark, Finland, Iceland, Norway and Sweden during the first year of the pandemic.
Results The Nordic countries differed markedly in the invasiveness of control strategies implemented. In particular, Sweden did not initially employ any strict population movement limitations and experienced markedly different transmission chain dynamics, which were more numerous and tended to have more cases, a set of features that increased with time during the first eight months of 2020.
Conclusion Together with Denmark, Sweden was also characterised as a net exporter of SARS-CoV-2. Hence, Sweden effectively constituted an epidemiological and evolutionary ‘refugia’ that enabled the virus to maintain active transmission and spread to other geographic localities. In sum, our analysis reveals the utility of genomic surveillance where active transmission chain monitoring is a key metric.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JHOP is funded by the Swedish research council FORMAS (grant no: 2015-710) and VR (grant no: 2020-02593). ECH is funded by an ARC Australian Laureate Fellowship (FL170100022). SD and LF are funded by an ARC Discovery Early Career Award awarded to SD (DE190100805).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Only open access sequence data via the GISAID platform had been used in this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing interest statement All authors have read the manuscript and have no conflict of interest to declare.
Funding statement JHOP is funded by the Swedish research council FORMAS (grant no: 2015-710) and VR (grant no: 2020-02593). ECH is funded by an ARC Australian Laureate Fellowship (FL170100022). SD and LF are funded by an ARC Discovery Early Career Award awarded to SD (DE190100805). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Revised following modelling of data between December 2019 to March 2021
Data Availability
Accession numbers to the sequence data used in the study (full data available at the GISAID platform) are available in supplementary table 2.
